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Abstract 
 
Co-chemotherapeutics approaches are increasing in cancer treatment in order mainly 
to suppress the resistence phenomenon of cancer treatment and to enhance the cytotoxic 
effect of the main chemotherapeutics agent. Tangeretin has been known to have cytotoxic 
effect to some cancer cells through some pathways in the cells. To explore the potential 
effect of tangeretin as co-chemotherapeutics agent this research was subjected to study the 
cytotoxic effect of tangeretin in combination with 5-Fluoro Uracil (5-FU) on WiDr colon 
cancer cells covering the modulation of cell cycle and apoptosis induction. Cytotoxic effect 
was examined by using MTT assay while apoptotis induction was determined by annexin-V 
flowcytometry. Under MTT assay, tangeretin showed weak cytotoxic activity on the cells. 
However, tangeretin significantly enhanced the cytotoxic effect of 5-FU on the cells. This co-
chemotherapeutics effect likely correlated with cell cycle modulation effect, especially in 
inducing polyploidy phenomenon as expressed in the flowcytometric graph of the DNA 
content. This combination also increased apoptosis induction. These result suggest that 
tangeretin is potential to be developed as co-chemotherapeutic agent for 5-Fu on colon 
cancer and further molecular mechanism need to be explored. 
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INTRODUCTION 
 
 Colon cancer has 3
rd
 highest incidence 
in United States. It is estimated about 106,100 
new cases and 49,200 death cases of colon 
cancer occurred in 2009 (Jemal, et al., 2009). 
One of first line therapy against colon cancer is 
5-Fluorouracl (5-Fu). Nevertheless, 5-Fu gave 
effectivity below 15% on colon cancer patient 
(Yoshikawa, et al., 2001). This phenomenon is 
expected due to chemoresistance caused by 
thymidilate synthetase overexpression 
(Giovannetti, et al., 2007). Thus, efforts are 
developed to overcome this phenomenon. 
Usually, 5-Fu is combined with other 
chemotherapeutic agents such as leucovorin 
(Zhang, et al., 1992), irinotecan, or oxaliplatin 
(Meyerhardt and Mayer, 2005). But, 
combination chemotherapy with other 
chemotherapeutic agent causes higher cost and 
adverse effect (Meyerhardt and  Mayer, 2005). 
 Tangeretin is polymethoxy flavon 
found in citrus peels. Tangeretin possesses 
antiproliferative activity, induce apoptosis, and 
cause cell cycle arrest against some cancer cells 
(Choi, et al., 2007; Pan, et al., 2002). This 
compound performed cytotoxic activity with 
IC50 less than 5 µM on melanoma cells (Yanez, 
et al., 2004), lung cancer, colon cancer, breast 
cancer, and prostate cancer cells (Manthey and 
Guthrie, 2002). Pan, et al. (2002) reported that 
tangeretin inhibits COLO 205 colon cancer cells 
through inhibiting Rb phosphorylation and 
CDK2/4 inhibition mediated G1 arrest. Those 
researches exhibits potency of tangeretin as 
chemoprevention agent. 
The aim of this study is to evaluate 
cytotoxicity, apoptosis induction, and cell cycle 
modulation of tangeretin combined with 5-Fu on 
Widr colon cancer cells. 
 
 
 
 
 
*Corresponding author e-mail: ririsjenie@gmail.com 
Indriyani, et al., 2012 
Indones. J. Cancer Chemoprevent., 3(1), 364-369 
 
 
365 
 
MATERIALS AND METHODS  
 
Materials 
Citrus flavonoid tangeretin were from 
Sigma (Cat no T8951-5MG). Chemotherapeutic 
agent 5-Fluorouracil ”Ebewe” 250mg/ml were 
from P.T. Ferron Par Pharmaceutical (Cikarang, 
Indonesia). Sample were dissolved in DMSO 
(DMSO 99,5% pro GC, Sigma Aldrich, 
Germany) as co-solven, and dilluted 1:50 with 
20 mg/ml of Bovine Serum Albumin (BSA) in 
PBS.  
 
Cell Culture 
Widr colon cancer cells was obtained 
from the collection of Laboratory of 
Parasitology, Faculty of Medicine, Universitas 
Gadjah Mada (UGM). Cells were grown in 
medium RPMI 1640 (Gibco, USA) containing 
fetal bovine serum (FBS) 10% (v/v) (FBS 
qualified, Gibco, USA), and penicillin-
streptomisin 1 % (v/v) (Gibco, USA). Cells 
were harvested using trypsin-EDTA 0,025% 
(Gibco, Canada). 
 
Cytotoxic Assay 
Cytotoxic assay was done using MTT [3-
4, 5-dimetiltiazol-2-yl)-2,5 difeniltetrazolium 
bromide] (Mosmann, 1983). Cells in 80% 
confluent were harvested and counted, then 
diluted with complete culture medium. The cells 
then were transferred into a 96-well plate with a 
total of 5 x 10
3
 cells/well followed by 48 hours 
incubation. After that, the sample was added to 
the wells at various concentrations with co-
solvent DMSO and incubated at 37
0
C in a 5% 
CO2 incubator for 24 hours. At the ends of 
incubation, 100 µL MTT reagent with 
concentration 0.5 mg/ml in DMEM was added 
into each well. The plate then incubated at 37
0
C 
for 3 hours until formazan was formed. If 
formazan was formed, stopper SDS 10% in 
0.01N HCl was added. Plate then was wrapped 
with paper or alumunium foil and incubated in 
dark condition overnight. Absorbance was 
determined with an ELISA reader at λ 595 nm. 
 
Cell Cycle and Apoptosis Analysis 
WiDr cells were seeded at 5 x 10
5
 
cells/well on six wells tissue culture plate. After 
24 hours incubation cells were treated with 
tangeretin alone and its combination with 5-Fu. 
After 24 h of these treatments, cells were 
trypsinized and cells pellets were collected. 
Cells were trypsinized, spin at 2000 rpm for 30 
seconds and washed twice with cold PBS. Cells 
were resuspended in propidium iodide solution 
(50 μg/mL in PBS contained 1% triton X-100) 
and then treated with RNAse DNAse free (20 
μg/mL) for 10 minutes at 37
0
C. The treated cells 
then subjected to FACS flowcytometry and data 
was analyzed by using ModFit LT 3.0 program. 
 
RESULTS AND DISCUSSION 
 
Cytotoxic Effect of Tangeretin and 5-Fu 
on WiDr Cells  
 In this study, both tangeretin and 5-Fu 
didn’t inhibit over 50% of WiDr cells,  thus IC50 
value couldn’t be obtained (Fig. 1A). However, 
tangeretin and 5-Fu treatment altered membrane 
permeability so that boundary between cells 
wasn’t clear. Treated cells also became more 
rounded (Fig.1B).   
 
Combination Effect of Tangeretin and 5-
Fu on WiDr Cells  
Combinational cytotoxic assay was done 
by combined 5-Fu (1150 and 2300 μM) with 
tangeretin (10, 50, dan 100 μM).  Tangeretin 
increased cytotoxic effect of 5-Fu significantly 
on WiDr cells compared to 5-Fu treatment alone 
(p<0.05) (Fig.2). However, WiDr cells viability 
remained high (>70%), indicating those 
combination need to be optimized. 
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Figure 1. Cytotoxic Effect of tangeretin and 5-Fu on WiDr Cells. WiDr cells (5000 cells/well) were 
seeded in 96 wellplate and incubated for 48h. Cell viability was determined by using MTT 
assay as described in methods. Graph between concentration and cells viability of (A) 
Tangeretin and (B) 5-Fu (B) showed low cytotoxic activity on WiDr cells. Nevertheless, 
treatment with both compounds altered cells morphology. Cells treated with (C) none, 
(D) tangeretin 50 µM, (E) 5-Fu 1150 µM, (F) 5-Fu 1150 µM and tangeretin 50 µM, and (G) 
5-Fu 2300 µM and tangeretin 100 µM. Black arrows (     ) showed viable cells while white 
arrows (      ) showed alteration of cells morphology. Cells were observed under light 
microscope with 100x magnifications. 
 
Figure 2. Combination Cytotoxic Effect of tangeretin and 5-Fu on WiDr Cells. WiDr cells (5000 
cells/well) were seeded in 96 wellplate and treated with tangeretin 10, 50, and 100 µM in 
combination with 5-Fu 1150 and 2300 µM, then incubated for 48h. Cells viability was 
determined by using MTT assay as described in methods. Tangeretin decreased cells 
viability compared to single 5-Fu treatment. Data were mean of 3 replications and 
analyzed using One way ANOVA. 
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Effect of Tangeretin and 5-Fu on Cell 
Cycle and Apoptosis  
Treatment with 5-Fu or tangeretin solely 
induced cells accumulation of the cells in 
subG1 phase and decreased cells in other 
phases. This phenomenon seems contrary with 
the cytotoxic result that showed no effect in 
decreasing cell viability. This contrary result 
may due to some debris following the assay, 
but, some debris could be representing some 
apoptotic evidence. Moreover, combination of 
them caused extensive cells accumulation in 
subG1 phase (73.12%) (Fig.3 and Table I), that 
may be representing some apoptotic cells. Thus, 
5-Fu, tangeretin, and combination of those 
compounds likely induced apoptosis 
extensively compared to untreated cells. 
 
 
Figure 3. Effect of Tangeretin and 5-Fu on Cell Cycle and Apoptosis. WiDr cells were treated with 5-
Fu and tangeretin then incubated for 24 hours. Cells then were harvested and prepared for 
flowcytometric analysis using PI as described in methods. Figures are distribution profiles 
of the cells treated with (A) none, (B) 5-Fu 2300 µM, (C) tangeretin 100 µM, (D) 5-Fu 2300 
µM and tangeretin 100 µM. 
 
Table I. Distribution of WiDr cells (%) after treatment with tangeretin and 5-Fu 
 
Treatment Phase  
Sub G1 G1 S G2/M 
None (control) 10, 59 54, 05 10, 76 10, 91 
5-FU 2300 µM  49, 20 32, 29 7, 38 6, 87 
Tangeretin 100 µM  64, 12 21, 68 6,70 4, 55 
Tangeretin 100 µM and 5-FU 2300 µM  73, 12 11, 25 8, 28 5, 83 
  
  This study exhibited low cytotoxic 
activity of tangeretin and the IC50 of tangeretin 
could not be obtained. Based on previous study, 
tangeretin targets p53 in cancer cells, while 
WiDr as the model in this study showed p53 
mutation (Noguchi, et al., 1979). This result 
probably caused low efficacy of tangeretin on 
WiDr cells. Beside, 5-Fu also showed low 
efficacy that may be due to WiDr cells 
resistance through PI3K/Akt activation 
(Benistan, et al., 2000). 
  Due to low efficacy of tangeretin 
solely, combination cytotoxic assay was done. 
Tangeretin increased 5-Fu cytotoxicity on WiDr 
cells. Furthermore, combination of tangeretin 
and 5-Fu likely caused excessive apoptosis. 
This can be effect of tangeretin to interfere 
PI3K/Akt pathway. Tangeretin also 
downregulated downstream of PI3K/Akt 
pathway, such as NF-κB (Arafa, et al., 2009). 
Downregulation of NF-κB leads to decrease of 
anti-apoptotic protein, such as Bcl-2, IAPs, and 
Bcl-xl. Other mechanism interfere by tangeretin 
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is p21 independent p53 expression, that may 
contribute in the apoptosis induction.  
  All of the data in this study showed 
that tangeretin improved the cytotoxic effect of 
5-FU on WiDR cells through apoptosis 
induction and cell cycle modulation. These 
results supported tangeretin to be developed as 
co-chemotherapeutic agent, especially to cure 
colon cancer that resistant to 5-FU. However, in 
order to lead for the application more precisely, 
the data should be more completed by exploring 
the specific targets of the agent as well as its 
effect in the in vivo experiment. 
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